This article was originally published in The Gray Sheet
Executive SummaryFDA guidance issued Aug. 2 recognizes five standards for use in abbreviated 510(k) applications. Cardiovascular brachytherapy devices for prevention of restenosis are not addressed by the document. While the guidance is appropriate for sponsors seeking general claims for photon-emitting brachytherapy sources, specific claims should be handled using the agency's "Guidance for Industry on General/Specific Intended Use"
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.